Disintegrin variants and pharmaceutical uses thereof

Woei-Jer Chuang (Inventor)

研究成果: Patent

摘要

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
原文English
專利號577998
出版狀態Published - 2012 三月 30

指紋

Disintegrins
Integrins
Pharmaceutical Preparations
Peptides

引用此文

@misc{e0243b130d1745eca4f1b01cc0254e4a,
title = "Disintegrin variants and pharmaceutical uses thereof",
abstract = "Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.",
author = "Woei-Jer Chuang",
year = "2012",
month = "3",
day = "30",
language = "English",
type = "Patent",
note = "577998",

}

TY - PAT

T1 - Disintegrin variants and pharmaceutical uses thereof

AU - Chuang, Woei-Jer

PY - 2012/3/30

Y1 - 2012/3/30

N2 - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

AB - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

M3 - Patent

M1 - 577998

ER -